BeiGene to Present at the Jefferies London Healthcare Conference
read more...
Nov 05, 2024
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
read more...
Oct 28, 2024
BeiGene Mourns Death of Beloved Board Member Donald Glazer
read more...
Oct 23, 2024
BeiGene Named Manufacturer of the Year by the National Association of Specialty Pharmacy (NASP)
read more...
Oct 21, 2024
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
read more...
Oct 16, 2024
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
read more...
Oct 04, 2024
BeiGene Announces Availability of TEVIMBRA® in U.S.
read more...
Sep 26, 2024
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
read more...
Sep 26, 2024
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
read more...
Sep 17, 2024
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
read more...
Sep 09, 2024
BeiGene Announces Updates to Commercial Leadership Team
read more...
Sep 09, 2024
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
read more...
Aug 28, 2024
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
read more...
Aug 26, 2024
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
read more...
Aug 07, 2024
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
read more...
Jul 23, 2024
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
read more...
Jul 18, 2024
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
read more...
Jun 14, 2024
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
read more...
Jun 04, 2024
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
read more...
May 24, 2024
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
read more...
